ANTI-INTERLEUKIN-11 RECEPTOR SUBUNIT ALPHA (IL-11RA) ANTIBODIES

1 . An antibody which binds to interleukin-11 receptor subunit α (IL-11Rα), wherein the antibody comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH comprises complementary determining region VHCDR1, VHCDR2, and VHCDR3 sequences and the VL comprises complementary determining region VLCDR1, VLCDR2, and VLCDR3 sequences, and wherein:

a. the VHCDR1, VHCDR2, and VHCDR3 sequences comprise SEQ ID NOs: 25-27, respectively, and the VLCDR1, VLCDR2, and VLCDR3 sequences comprise SEQ ID NOs: 28-30, respectively;

b. the VHCDR1, VHCDR2, and VHCDR3 sequences comprise SEQ ID NOs: 91-93, respectively, and the VLCDR1, VLCDR2, and VLCDR3 sequences comprise SEQ ID NOs: 94-96, respectively;

c. the VHCDR1, VHCDR2, and VHCDR3 sequences comprise SEQ ID NOs: 97-99, respectively, and the VLCDR1, VLCDR2, and VLCDR3 sequences comprise SEQ ID NOs: 100-102, respectively;

d. the VHCDR1, VHCDR2, and VHCDR3 sequences comprise SEQ ID NOs: 103-105, respectively, and the VLCDR1, VLCDR2, and VLCDR3 sequences comprise SEQ ID NOs: 106-108, respectively;

e. the VHCDR1, VHCDR2, and VHCDR3 sequences comprise SEQ ID NOs: 109-111, respectively, and the VLCDR1, VLCDR2, and VLCDR3 sequences comprise SEQ ID NOs: 112-114, respectively;

f. the VHCDR1, VHCDR2, and VHCDR3 sequences comprise SEQ ID NOs: 115-117, respectively, and the VLCDR1, VLCDR2, and VLCDR3 sequences comprise SEQ ID NOs: 118-120, respectively;

g. the VHCDR1, VHCDR2, and VHCDR3 sequences comprise SEQ ID NOs: 121-123, respectively, and the VLCDR1, VLCDR2, and VLCDR3 sequences comprise SEQ ID NOs: 124-126, respectively;

h. the VHCDR1, VHCDR2, and VHCDR3 sequences comprise SEQ ID NOs: 127-129, respectively, and the VLCDR1, VLCDR2, and VLCDR3 sequences comprise SEQ ID NOs: 130-132, respectively;

i. the VHCDR1, VHCDR2, and VHCDR3 sequences comprise SEQ ID NOs: 133-135, respectively, and the VLCDR1, VLCDR2, and VLCDR3 sequences comprise SEQ ID NOs: 136-138, respectively;

j. the VHCDR1, VHCDR2, and VHCDR3 sequences comprise SEQ ID NOs: 139-141, respectively, and the VLCDR1, VLCDR2, and VLCDR3 sequences comprise SEQ ID NOs: 142-144, respectively;

k. the VHCDR1, VHCDR2, and VHCDR3 sequences comprise SEQ ID NOs: 145-147, respectively, and the VLCDR1, VLCDR2, and VLCDR3 sequences comprise SEQ ID NOs: 148-150, respectively;

l. the VHCDR1, VHCDR2, and VHCDR3 sequences comprise SEQ ID NOs: 151-153, respectively, and the VLCDR1, VLCDR2, and VLCDR3 sequences comprise SEQ ID NOs: 154-156, respectively;

m. the VHCDR1, VHCDR2, and VHCDR3 sequences comprise SEQ ID NOs: 157-159, respectively, and the VLCDR1, VLCDR2, and VLCDR3 sequences comprise SEQ ID NOs: 160-162, respectively;

n. the VHCDR1, VHCDR2, and VHCDR3 sequences comprise SEQ ID NOs: 163-165, respectively, and the VLCDR1, VLCDR2, and VLCDR3 sequences comprise SEQ ID NOs: 166-168, respectively;

o. the VHCDR1, VHCDR2, and VHCDR3 sequences comprise SEQ ID NOs: 169-171, respectively, and the VLCDR1, VLCDR2, and VLCDR3 sequences comprise SEQ ID NOs: 172-174, respectively;

p. the VHCDR1, VHCDR2, and VHCDR3 sequences comprise SEQ ID NOs: 175-177, respectively, and the VLCDR1, VLCDR2, and VLCDR3 sequences comprise SEQ ID NOs: 178-180, respectively;

q. the VHCDR1, VHCDR2, and VHCDR3 sequences comprise SEQ ID NOs: 181-183, respectively, and the VLCDR1, VLCDR2, and VLCDR3 sequences comprise SEQ ID NOs: 184-186, respectively; or

r. the VHCDR1, VHCDR2, and VHCDR3 sequences comprise SEQ ID NOs: 187-189, respectively, and the VLCDR1, VLCDR2, and VLCDR3 sequences comprise SEQ ID NOs: 190-192, respectively; and

wherein the antibody comprises a modified Fc domain that exhibits an increased half-life and/or a low effector function in humans, relative to a corresponding wild-type Fc sequence.

2 . The antibody of claim 1 , wherein:

a. the VH comprises a sequence of SEQ ID NO: 201, or a sequence comprising at least 80% sequence identity thereto; and the VL comprises a sequence of SEQ ID NO: 202, or a sequence comprising at least 80% sequence identity thereto;

b. the VH comprises a sequence of SEQ ID NO: 223, or a sequence comprising at least 80% sequence identity thereto; and the VL comprises a sequence of SEQ ID NO: 224, or a sequence comprising at least 80% sequence identity thereto;

c. the VH comprises a sequence of SEQ ID NO: 225, or a sequence comprising at least 80% sequence identity thereto; and the VL comprises a sequence of SEQ ID NO: 226, or a sequence comprising at least 80% sequence identity thereto;

d. the VH comprises a sequence of SEQ ID NO: 227, or a sequence comprising at least 80% sequence identity thereto; and the VL comprises a sequence of SEQ ID NO: 228, or a sequence comprising at least 80% sequence identity thereto;

e. the VH comprises a sequence of SEQ ID NO: 229, or a sequence comprising at least 80% sequence identity thereto; and the VL comprises a sequence of SEQ ID NO: 230, or a sequence comprising at least 80% sequence identity thereto;

f. the VH comprises a sequence of SEQ ID NO: 231, or a sequence comprising at least 80% sequence identity thereto; and the VL comprises a sequence of SEQ ID NO: 232, or a sequence comprising at least 80% sequence identity thereto;

g. the VH comprises a sequence of SEQ ID NO: 233, or a sequence comprising at least 80% sequence identity thereto; and the VL comprises a sequence of SEQ ID NO: 234, or a sequence comprising at least 80% sequence identity thereto;

h. the VH comprises a sequence of SEQ ID NO: 235, or a sequence comprising at least 80% sequence identity thereto; and the VL comprises a sequence of SEQ ID NO: 236, or a sequence comprising at least 80% sequence identity thereto;

i. the VH comprises a sequence of SEQ ID NO: 237, or a sequence comprising at least 80% sequence identity thereto; and the VL comprises a sequence of SEQ ID NO: 238, or a sequence comprising at least 80% sequence identity thereto;

j. the VH comprises a sequence of SEQ ID NO: 239, or a sequence comprising at least 80% sequence identity thereto; and the VL comprises a sequence of SEQ ID NO: 240, or a sequence comprising at least 80% sequence identity thereto;

k. the VH comprises a sequence of SEQ ID NO: 241, or a sequence comprising at least 80% sequence identity thereto; and the VL comprises a sequence of SEQ ID NO: 242, or a sequence comprising at least 80% sequence identity thereto;

l. the VH comprises a sequence of SEQ ID NO: 243, or a sequence comprising at least 80% sequence identity thereto; and the VL comprises a sequence of SEQ ID NO: 244, or a sequence comprising at least 80% sequence identity thereto;

m. the VH comprises a sequence of SEQ ID NO: 245, or a sequence comprising at least 80% sequence identity thereto; and the VL comprises a sequence of SEQ ID NO: 246, or a sequence comprising at least 80% sequence identity thereto;

n. the VH comprises a sequence of SEQ ID NO: 247, or a sequence comprising at least 80% sequence identity thereto; and the VL comprises a sequence of SEQ ID NO: 248, or a sequence comprising at least 80% sequence identity thereto;

o. the VH comprises a sequence of SEQ ID NO: 249, or a sequence comprising at least 80% sequence identity thereto; and the VL comprises a sequence of SEQ ID NO: 250, or a sequence comprising at least 80% sequence identity thereto;

p. the VH comprises a sequence of SEQ ID NO: 251, or a sequence comprising at least 80% sequence identity thereto; and the VL comprises a sequence of SEQ ID NO: 252, or a sequence comprising at least 80% sequence identity thereto;

q. the VH comprises a sequence of SEQ ID NO: 253, or a sequence comprising at least 80% sequence identity thereto; and the VL comprises a sequence of SEQ ID NO: 254, or a sequence comprising at least 80% sequence identity thereto; or

r. the VH comprises a sequence of SEQ ID NO: 255, or a sequence comprising at least 80% sequence identity thereto; and the VL comprises a sequence of SEQ ID NO: 256, or a sequence comprising at least 80% sequence identity thereto.

3 . The antibody of claim 1 , wherein the low effector function is selected from one or more of the following: decreased complement fixation or activation, decreased C1q binding affinity, decreased CDC-related activity, decreased FcR binding affinity, decreased ADCC-related activity, and decreased ADCP-related activity, relative to a corresponding wild-type Fc sequence.

4 . The antibody of claim 1 , wherein the modified Fc domain comprises one or more substitutions selected from the group consisting of L234A, L235A, M252Y, S254T, T256E and P329S, or substitutions at a residue corresponding thereto, relative to the wild-type Fc sequence, according to EU numbering.

5 . The antibody of claim 3 , wherein the modified Fc domain further comprises an S228P substitution, or substitutions at a residue corresponding thereto, according to EU numbering.

6 . The antibody of claim 1 , wherein the modified Fc domain is a human IgG4 domain comprising the substitutions S228P, M252Y, S254T, and T256E, or substitutions at a residue corresponding thereto, relative to the wild-type Fc sequence, according to EU numbering.

7 . The antibody of claim 1 , wherein the modified Fc domain is a human IgG1 domain comprising the substitutions L234A, L235A, P329S, M252Y, S254T, and T256E, or substitutions at a residue corresponding thereto, relative to the wild-type Fc sequence, according to EU numbering.

8 . The antibody of claim 1 , wherein the modified Fc domain is a human IgG4 domain comprising the substitutions S228P, M252Y, S254T, and T256E, or substitutions at a residue corresponding thereto, relative to the wild-type Fc sequence, according to EU numbering.

9 . The antibody of claim 2 , wherein the modified Fc domain is a human IgG4 domain comprising the substitutions S228P, M252Y, S254T, and T256E, or substitutions at a residue corresponding thereto, relative to the wild-type Fc sequence, according to EU numbering.

10 . The antibody of claim 2 , wherein the modified Fc domain is a human IgG1 domain comprising the substitutions L234A, L235A, P329S, M252Y, S254T, and T256E, or substitutions at a residue corresponding thereto, relative to the wild-type Fc sequence, according to EU numbering.

11 . The antibody of claim 2 , wherein the modified Fc domain is a human IgG4 domain comprising the substitutions S228P, M252Y, S254T, and T256E, or substitutions at a residue corresponding thereto, relative to the wild-type Fc sequence, according to EU numbering.

12 . The antibody of claim 1 , wherein the modified Fc domain is a modified human Fc domain.

13 . The antibody of claim 1 , wherein the modified Fc domain is an IgA, IgD, IgE, IgG, or IgM Fc domain.

14 . The antibody of claim 13 , wherein the modified IgG Fc domain is an IgG1, IgG2, IgG3, and IgG4 domain.

15 . The antibody of claim 13 , wherein the modified IgA Fc domain is an IgA1 or IgA2 domain.

16 . The antibody of claim 1 , wherein the antibody, or antigen binding fragment thereof, is a monoclonal antibody.

17 . The antibody of claim 1 , which is selected from the group consisting of an Fv fragment, a single chain Fv (scFv) polypeptide, an adnectin, an anticalin, an aptamer, an avimer, a camelid antibody, a designed ankyrin repeat protein (DARPin), a minibody, a nanobody, and a unibody.

18 . The antibody of claim 1 , which binds to a fibronectin domain III of human IL-11Rα, or to approximately residues 112-219 of SEQ ID NO: 257.

19 . A pharmaceutical composition comprising a pharmaceutically acceptable carrier and the antibody of claim 1 .